



australasian society of clinical immunology and allergy

20 January 2023

Professor Andrew Wilson
Chair, Pharmaceutical Benefits Advisory Committee (PBAC)
MDP 952, GPO Box 9848
Canberra, ACT 2601
Email: pbac@health.gov.au

Dear Professor Wilson,

Re: EleCare® LCP application

This submission is made on behalf of the Australasian Society of Clinical Immunology and Allergy (ASCIA). ASCIA is the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand.

We write in support of the following application which is on the March 2023 meeting agenda for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC), for continued Pharmaceutical Benefits Scheme (PBS) listing under the current conditions:

AMINO ACID SYNTHETIC FORMULA SUPPLEMENTED WITH LONG CHAIN POLYUNSATURATED (LCP) FATTY ACIDS

EleCare® LCP - Abbott Australasia Pty Ltd

Oral powder 400g

Clinical indications: Cow's milk anaphylaxis, severe cow's milk protein enteropathy with failure to thrive, combined intolerance to cow's milk protein, soy protein and protein hydrolysate formulae, cow's milk anaphylaxis, proven combined immunoglobulin E (IgE) mediated allergy to cow's milk protein and soy protein, severe intestinal malabsorption including short bowel syndrome.

Proposed update to PBS listing: To request that EleCare LCP with new source of docosahexaenoic acid (DHA) continue to be listed on the PBS under the current conditions.

ASCIA supports this application for the following reasons:

- There is an important clinical need for medical nutrition products, including **EleCare® LCP**, for the management of infants and children with cow's milk allergy (CMA) and multiple food protein allergy. To ensure equitable access and mitigate the risk of supply issues, it is critical to have multiple brands of clinically indicated medical nutrition products available on the PBS.
- Any changes to the current PBS listing conditions, such as cost reduction of amino acid formula, will result in brands of medical nutrition products on the PBS no longer being financially viable for suppliers in Australia. This will have a significant impact on the nutrition and health outcomes for children with CMA and multiple food protein allergy and their families.

We hope that the PBAC will take into account the reasons listed above, in support of the application for continued PBS listing of **EleCare® LCP** under the current conditions.

Please do not hesitate to contact us by emailing jill@allergy.org.au for further information.

Yours sincerely,

A/Prof Theresa Cole

ASCIA President

Jill Smith

ASCIA CEO

Copy: ASCIA Council